Immunogenicity and safety of a virosomal hepatitis A vaccine in HIV-positive patients

Abstract This short report presents results of an open uncontrolled single centre study which evaluated immunogenicity and safety of a virosome-formulated hepatitis A vaccine (Epaxal® ) in 14 HIV-positive adult patients and 64 healthy adults receiving a primary immunisation and a booster dose 12 mon...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2007-08, Vol.25 (34), p.6310-6312
Main Authors: Loutan, L, Bovier, P, Herzog, C
Format: Article
Language:English
Subjects:
Adult
Age
Allergy and Immunology
Aluminum
Antiretroviral drugs
Applied microbiology
Biological and medical sciences
Fundamental and applied biological sciences. Psychology
Hepatitis
Hepatitis A Antibodies - blood
Hepatitis A vaccine
Hepatitis A Vaccines - adverse effects
Hepatitis A Vaccines - immunology
HIV
HIV Seropositivity - immunology
Human immunodeficiency virus
Human viral diseases
Humans
Immunization
Immunogenicity
Infectious diseases
Male
Medical sciences
Microbiology
Miscellaneous
Patients
Safety
Studies
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Vaccines, Virosome - adverse effects
Vaccines, Virosome - immunology
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Viral hepatitis
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract This short report presents results of an open uncontrolled single centre study which evaluated immunogenicity and safety of a virosome-formulated hepatitis A vaccine (Epaxal® ) in 14 HIV-positive adult patients and 64 healthy adults receiving a primary immunisation and a booster dose 12 months later. Seroconversion rates (≥20 mIU/mL), geometric mean concentration (GMC) of anti-HAV antibodies, local and systemic adverse events (AEs) were assessed at baseline and at Months 1, 6, 12, and 13. The seroconversion rate was 63.6% at Month 1 and 91.7% at Month 13 in HIV-positive patients versus 93.8 and 100% in healthy adults. The booster dose increased GMCs from 25.5 to 659.2 mIU/mL in HIV-positive patients versus 104 and 2986 mIU/mL in healthy adults. Epaxal® was well tolerated by the HIV-positive patients and was at least as immunogenic as reported for aluminium-adsorbed vaccines. In conclusion, Epaxal® can be considered an immunogenic and safe hepatitis A vaccine in HIV-positive patients.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2007.06.013